Peptide Cancer Vaccine Market
- 2026 年市場規模
- USD 1.8 Bn
- 2033 年預估規模
- USD 8.2 Bn
- 年複合成長率 CAGR
- 24.3%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Peptide Cancer Vaccine Market, By Pipeline Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, and Phase III), By Application (Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Gastric Cancer, Prostate Cancer, and Breast Cancer), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
The Peptide Cancer Vaccine Market is estimated to be valued at USD 1.8 Bn in 2026 and is expected to reach USD 8.2 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 24.3% from 2026 to 2033. The market is undergoing a major transformation mainly driven by rising adoption of personalized cancer immunotherapies, increasing demand for targeted treatment options, and growing emphasis on antitumor immune response solutions. Peptide cancer vaccines, including personalized, shared-antigen, and multipeptide formulations, enable immunity to recognize tumor antigens efficiently while addressing tumor heterogeneity, immune escape, and safety standards. The market includes a wide array of product applications like melanoma, lung cancer, breast cancer, prostate cancer, gastrointestinal cancers, hematological malignancies, and solid tumor treatment.
Patients and healthcare providers are focusing on precise immune activation and therapeutic approaches to enhance treatment outcomes, ensure tumor control, and maintain quality of life. The advancements in neoantigen identification, peptide synthesis, and adjuvant delivery tools are improving vaccine performance, especially in patients with treatment-resistant or recurrent cancers. In addition, the growing use of genomic sequencing and combination immunotherapy regimens helps optimize patient selection and immune response, thereby improving clinical outcomes and reducing burden of cancer treatment.
Market Dynamics
The market is witnessing major momentum owing to increasing prevalence of cancer, rising investment in tumor-specific immunotherapy, and the growing need for treatments capable of generating durable immune responses. The market’s growth is largely driven by biotechnology companies and research institutions seeking precise, adaptable, and safe therapeutic vaccine platforms, especially for melanoma, glioblastoma, prostate cancer, ovarian cancer, pancreatic cancer, and other malignancies requiring targeted immune intervention. Tumor-associated antigens, synthetic peptides, immune adjuvants, and antigen-presenting cell technologies play a central role in vaccine development, thereby helping activate cytotoxic T cells, improve tumor recognition, and limit disease progression. The rising focus on individualized treatment, recurrence prevention, and immune-based oncology is strengthening the demand for peptide cancer vaccines.
The expansion of neoantigen discovery programs is fueling market growth. This is mainly driven by increasing adoption of genomic profiling, availability of advanced peptide synthesis platforms, and biomarker-guided vaccines designed according to tumor mutations. Combination approaches involving checkpoint inhibitors, chemotherapy, and immune-stimulating agents help improve response rates and overcome tumor-induced immune suppression.
The rising demand for less toxic cancer therapies is also propelling the market. Oncologists, immunologists, clinical researchers, pharmaceutical developers, diagnostic laboratories, and specialized cancer centers play a crucial role in evaluating and advancing peptide vaccine candidates. As understanding of tumor immunology grows, the market is expected to benefit from clinical development, improved patient selection, and the introduction of more personalized, effective, and scalable cancer vaccination solutions.
Key Features of the Study
• This report provides in-depth analysis of the Peptide Cancer Vaccine Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Peptide Cancer Vaccine Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Marker Therapeutics, Inc., Agenus, Merck, BrightPath Biotherapeutics, Boston Biomedical, VAXON Biotech, Nouscom, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, OncoTherapy Science, Enzo Life Science, Immatics Biotechnologies, SELLAS Life Sciences Group, Ultimovacs, Celldex therapeutics, Immunomic Therapeutics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Peptide Cancer Vaccine Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Peptide Cancer Vaccine Market
Market Segmentation
• By Pipeline Phase (Revenue, USD Bn, 2021-2033)
o Research
o Preclinical
o Phase-I
o Phase-I/II
o Phase-II
o Phase-III
• By Application (Revenue, USD Bn, 2021-2033)
o Colorectal Cancer
o Lung Cancer
o Pancreatic Cancer
o Gastric Cancer
o Prostate Cancer
o Breast Cancer
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players Insights
o Marker Therapeutics, Inc.
o Agenus
o Merck
o BrightPath Biotherapeutics
o Boston Biomedical
o VAXON Biotech
o Nouscom
o Lytix Biopharma
o ISA Pharmaceuticals
o Generex Biotechnology
o OncoTherapy Science
o Enzo Life Science
o Immatics Biotechnologies
o SELLAS Life Sciences Group
o Ultimovacs
o Celldex therapeutics
o Immunomic Therapeutics, Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Pipeline Phase
Market Snapshot, By Application
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Disease Type Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Peptide Cancer Vaccine Market, By Pipeline Phase, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Research
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Preclinical
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Phase-I
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Phase-I/II
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Phase-II
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Phase-III
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Peptide Cancer Vaccine Market, By Application, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Colorectal Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Lung Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Pancreatic Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Gastric Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Prostate Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Breast Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Peptide Cancer Vaccine Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Marker Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Agenus
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Merck
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
BrightPath Biotherapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Boston Biomedical
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
VAXON Biotech
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Nouscom
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Lytix Biopharma
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
ISA Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Generex Biotechnology
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
OncoTherapy Science
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Enzo Life Science
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Immatics Biotechnologies
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
SELLAS Life Sciences Group
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ultimovacs
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Celldex therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Immunomic Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們